Q4 2018 13F Holders as of 12/31/2018
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
47.9M
-
Number of holders
-
276
-
Total 13F shares, excl. options
-
50.4M
-
Shares change
-
-1.35M
-
Total reported value, excl. options
-
$5.05B
-
Value change
-
-$150M
-
Put/Call ratio
-
2.89
-
Number of buys
-
127
-
Number of sells
-
-153
-
Price
-
$100.05
Significant Holders of HAEMONETICS CORP - Common Stock (HAE) as of Q4 2018
337 filings reported holding HAE - HAEMONETICS CORP - Common Stock as of Q4 2018.
HAEMONETICS CORP - Common Stock (HAE) has 276 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 50.4M shares
.
Largest 10 shareholders include BlackRock Inc. (6.03M shares), Vanguard Group Inc (5.62M shares), WELLINGTON MANAGEMENT GROUP LLP (4.95M shares), RENAISSANCE TECHNOLOGIES LLC (2.42M shares), STATE STREET CORP (1.66M shares), Jackson Square Partners, LLC (1.47M shares), Neuberger Berman Group LLC (1.42M shares), Capital Research Global Investors (1.41M shares), HealthCor Management, L.P. (1.1M shares), and DIMENSIONAL FUND ADVISORS LP (1.02M shares).
This table shows the top 276 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.